DLL3 and small cell lung carcinoma: For example, ABBV-181, a humanized anti-PD-1 monoclonal antibody, was tested in combination with ROVA-T, an antibody-drug conjugate targeting DLL3, in small cell lung cancer (SCLC) patients.